Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non-small cell lung cancer

被引:12
作者
Aramini, Beatrice [1 ]
Masciale, Valentina [2 ]
Samarelli, Anna Valeria [2 ]
Dubini, Alessandra [3 ]
Gaudio, Michele [3 ]
Stella, Franco [1 ]
Morandi, Uliano [4 ]
Dominici, Massimo [2 ]
De Biasi, Sara [5 ]
Gibellini, Lara [5 ]
Cossarizza, Andrea [5 ,6 ]
机构
[1] Univ Bologna, GB Morgagni L Pierantoni Hosp, Dept Expt Diag & Specialty Med DIME, Div Thorac Surg,Alma Mater Studiorum, Forli, Italy
[2] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Div Oncol & Lab Cellular Therapies, Modena, Italy
[3] GB Morgagni L Pierantoni Hosp, Div Pathol, Forli, Italy
[4] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Div Thorac Surg, Modena, Italy
[5] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy
[6] Natl Inst Cardiovasc Res, Bologna, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
NSCLC; tumor infiltrated immune cells; immunometabolism; cancer stem cells; tumor-infiltrating myeloid cells; TUMOR-ASSOCIATED MACROPHAGES; TERTIARY LYMPHOID STRUCTURES; REGULATORY T-CELLS; DENDRITIC CELLS; PROGNOSTIC VALUE; DIFFERENTIATION; NEUTROPHILS; PROMOTES; TISSUE; EXPRESSION;
D O I
10.3389/fimmu.2022.959114
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lung cancer is the leading cancer in the world, accounting for 1.2 million of new cases annually, being responsible for 17.8% of all cancer deaths. In particular, non-small cell lung cancer (NSCLC) is involved in approximately 85% of all lung cancers with a high lethality probably due to the asymptomatic evolution, leading patients to be diagnosed when the tumor has already spread to other organs. Despite the introduction of new therapies, which have improved the long-term survival of these patients, this disease is still not well cured and under controlled. Over the past two decades, single-cell technologies allowed to deeply profile both the phenotypic and metabolic aspects of the immune cells infiltrating the TME, thus fostering the identification of predictive biomarkers of prognosis and supporting the development of new therapeutic strategies. In this review, we discuss phenotypic and functional characteristics of the main subsets of tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating myeloid cells (TIMs) that contribute to promote or suppress NSCLC development and progression. We also address two emerging aspects of TIL and TIM biology, i.e., their metabolism, which affects their effector functions, proliferation, and differentiation, and their capacity to interact with cancer stem cells.
引用
收藏
页数:14
相关论文
共 155 条
  • [1] Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
    Al-Shibli, Khalid I.
    Donnem, Tom
    Al-Saad, Samer
    Persson, Magnus
    Bremnes, Roy M.
    Busund, Lill-Tove
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (16) : 5220 - 5227
  • [2] Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
    Albrengues, Jean
    Shields, Mario A.
    Ng, David
    Park, Chun Gwon
    Ambrico, Alexandra
    Poindexter, Morgan E.
    Upadhyay, Priya
    Uyeminami, Dale L.
    Pommier, Arnaud
    Kuttner, Victoria
    Bruzas, Emilis
    Maiorino, Laura
    Bautista, Carmelita
    Carmona, Ellese M.
    Gimotty, Phyllis A.
    Fearon, Douglas T.
    Chang, Kenneth
    Lyons, Scott K.
    Pinkerton, Kent E.
    Trotman, Lloyd C.
    Goldberg, Michael S.
    Yeh, Johannes T. -H.
    Egeblad, Mikala
    [J]. SCIENCE, 2018, 361 (6409) : 1353 - +
  • [3] Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
    Aldea, Mihaela
    Andre, Fabrice
    Marabelle, Aurelien
    Dogan, Semih
    Barlesi, Fabrice
    Soria, Jean-Charles
    [J]. CANCER DISCOVERY, 2021, 11 (04) : 874 - 899
  • [4] Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC
    Almatroodi, S. A.
    McDonald, C. F.
    Darby, I. A.
    Pouniotis, D. S.
    [J]. CANCER MICROENVIRONMENT, 2016, 9 (01) : 1 - 11
  • [5] Supporting the Next Generation of Scientists to Lead Cancer Immunology Research
    Alspach, Elise
    Chow, Ryan D.
    Demehri, Shadmehr
    Guerriero, Jennifer L.
    Gujar, Shashi
    Hartmann, Felix J.
    Helmink, Beth A.
    Hudson, William H.
    Ho, Won Jin
    Ma, Leyuan
    Maier, Barbara B.
    Maltez, Vivien, I
    Miller, Brian C.
    Moran, Amy E.
    Parry, Erin M.
    Pillai, Padmini S.
    Rafiq, Sarwish
    Reina-Campos, Miguel
    Rosato, Pamela C.
    Rudqvist, Nils-Petter
    Ruhland, Megan K.
    Sagiv-Barfi, Idit
    Sahu, Avinash Das
    Samstein, Robert M.
    Schuerch, Christian M.
    Sen, Debattama R.
    Thommen, Daniela S.
    Wolf, Yochai
    Zappasodi, Roberta
    [J]. CANCER IMMUNOLOGY RESEARCH, 2021, 9 (11) : 1245 - 1251
  • [6] The lung microenvironment: an important regulator of tumour growth and metastasis
    Altorki, Nasser K.
    Markowitz, Geoffrey J.
    Gao, Dingcheng
    Port, Jeffrey L.
    Saxena, Ashish
    Stiles, Brendon
    McGraw, Timothy
    Mittal, Vivek
    [J]. NATURE REVIEWS CANCER, 2019, 19 (01) : 9 - 31
  • [7] IRF4 instructs effector Treg differentiation and immune suppression in human cancer
    Alvisi, Giorgia
    Brummelman, Jolanda
    Puccio, Simone
    Mazza, Emilia M. C.
    Tomada, Elisa Paoluzzi
    Losurdo, Agnese
    Zanon, Veronica
    Peano, Clelia
    Colombo, Federico S.
    Scarpa, Alice
    Alloisio, Marco
    Vasanthakumar, Ajithkumar
    Roychoudhuri, Rahul
    Kallikourdis, Marinos
    Pagani, Massimiliano
    Lopci, Egesta
    Novellis, Pierluigi
    Blume, Jonas
    Kallies, Axel
    Veronesi, Giulia
    Lugli, Enrico
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (06) : 3137 - 3150
  • [8] The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies
    Bald, Tobias
    Krummel, Matthew F.
    Smyth, Mark J.
    Barry, Kevin C.
    [J]. NATURE IMMUNOLOGY, 2020, 21 (08) : 835 - 847
  • [9] Cancer stem cell-immune cell crosstalk in tumour progression
    Bayik, Defne
    Lathia, Justin D.
    [J]. NATURE REVIEWS CANCER, 2021, 21 (08) : 526 - 536
  • [10] Engineering nanomedicines for improved melanoma therapy: progress and promises
    Bei, Di
    Meng, Jianing
    Youan, Bi-Botti C.
    [J]. NANOMEDICINE, 2010, 5 (09) : 1385 - 1399